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Abstract
Reduced basal ganglia function has been associated with fatigue in neurologic disorders, as well as in patients exposed to
chronic immune stimulation. Patients with chronic fatigue syndrome (CFS) have been shown to exhibit symptoms
suggestive of decreased basal ganglia function including psychomotor slowing, which in turn was correlated with fatigue. In
addition, CFS patients have been found to exhibit increased markers of immune activation. In order to directly test the
hypothesis of decreased basal ganglia function in CFS, we used functional magnetic resonance imaging to examine neural
activation in the basal ganglia to a reward-processing (monetary gambling) task in a community sample of 59 male and
female subjects, including 18 patients diagnosed with CFS according to 1994 CDC criteria and 41 non-fatigued healthy
controls. For each subject, the average effect of winning vs. losing during the gambling task in regions of interest (ROI)
corresponding to the caudate nucleus, putamen, and globus pallidus was extracted for group comparisons and
correlational analyses. Compared to non-fatigued controls, patients with CFS exhibited significantly decreased activation in
the right caudate (p = 0.01) and right globus pallidus (p = 0.02). Decreased activation in the right globus pallidus was
significantly correlated with increased mental fatigue (r2 = 0.49, p = 0.001), general fatigue (r2 = 0.34, p = 0.01) and reduced
activity (r2 = 0.29, p = 0.02) as measured by the Multidimensional Fatigue Inventory. No such relationships were found in
control subjects. These data suggest that symptoms of fatigue in CFS subjects were associated with reduced responsivity of
the basal ganglia, possibly involving the disruption of projections from the globus pallidus to thalamic and cortical
networks.
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Introduction
There has been increasing interest in the neural correlates of
fatigue and other symptoms that afflict individuals with chronic
fatigue syndrome (CFS). CFS has devastating effects on social and
occupational function, leading to significant personal and public
health costs [1–4]. One potential focus for the neurocircuitry of
fatigue in CFS is the basal ganglia. The basal ganglia play a
fundamental role in the regulation of motor activity and
motivation and have been implicated as a major brain system
associated with fatigue [5]. For example, fatigue is common in
patients with neurologic disorders that involve the basal ganglia
including Parkinson’s disease and multiple sclerosis as well as in
human immunodeficiency virus (HIV), where infected patients
exhibit early cognitive/motor disturbances [5–9]. In addition,
lesions of the basal ganglia have been associated with marked
fatigue as well as psychomotor slowing [5–7]. In CFS patients,
neurocognitive testing has also revealed specific impairments
compatible with basal ganglia dysfunction, including motor
slowing that correlated with severity of fatigue [10]. In addition,
using magnetic resonance spectroscopy, CFS patients have shown
increased basal ganglia choline concentrations, possible evidence
of increased inflammation (glial activation) and/or ischemia [11].
Of note, increased peripheral blood markers of inflammation have
been reported in CFS subjects [12–15], and chronic fatigue is
often the outcome of a number of viral infections [16–18].
Interestingly, administration of inflammatory stimuli has been
shown to alter basal ganglia function in association with fatigue
[19]. Indeed, using functional magnetic resonance imaging
(fMRI), chronic administration of the anti-viral and inflammatory
cytokine interferon alpha was shown to reduce the neural response
of the basal ganglia (ventral striatum) to a hedonic reward task
[19], and changes in neural activity were in turn highly correlated
with symptoms of fatigue [19]. Similar results have been found
after acute administration of endotoxin to healthy volunteers
where the basal ganglia response to hedonic reward was found to
be reduced [20]. Taken together, these data suggest that
inflammatory stimuli including viruses, cytokines and cytokine
inducers can cause fatigue through alterations in basal ganglia
function.
In order to further explore basal ganglia function in patients
with CFS and its relationship with CFS-related symptoms, we
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conducted a fMRI study in CFS patients to examine the basal
ganglia response to hedonic reward during a gambling task
previously shown to activate relevant basal ganglia nuclei [21].
The correlation of the observed degree of neural activation in
relevant basal ganglia nuclei with symptoms of fatigue was also
assessed.
Materials and Methods
Ethics Statement
The study was approved a priori by the Emory and Centers for
Disease Control and Prevention Institutional Review Boards. All
subjects provided written informed consent prior to study
participation.
Subjects
Participants in this study represent a subgroup of persons
enrolled in the baseline and follow-up survey of CFS in Georgia
[1]. In brief, the baseline survey took place in 2004–2005 and used
random-digit-dialing screening interview followed by detailed
phone interview to identify participants who met interview criteria
for CFS (CFS-like), those who were well (control), or those with
some CFS case-defining symptoms (intermediate group). All CFS-
like participants, controls (matched to CFS-like on age, sex, race
and geographic strata), and a similar number of randomly selected
participants from the intermediate groups were invited for clinical
evaluation. The clinical visit included detailed medical history,
physical examination, laboratory tests, psychiatric screen, and
questionnaires to measure functional status, impairment and
symptoms, and was completed by 783 persons. Participants were
classified as: i) CFS cases, according to the 1994 case definition
[22,23]; ii) non-fatigued controls; iii) insufficient symptoms or
fatigue for CFS; or iv) exclusionary medical or psychiatric
condition. Demographic information, including education, was
collected during the telephone interview and verified in the clinic.
Follow-up occurred during 2007–2009 and included all baseline
participants without permanent exclusionary conditions seen in
clinic (n = 681) as well as those completing detailed telephone
interview (n= 3049). Participants were re-interviewed by phone
and invited for follow-up clinical examination. Participants in the
baseline detailed telephone interview who had no exclusions were
also contacted again and re-interviewed as part of the follow-up.
The follow-up clinic evaluated 751 participants and classified them
in the manner described above. Following clinical and laboratory
assessments, 71 persons met criteria for CFS, and 212 were
determined to be controls. Medical and psychological exclusions
for CFS include history of head trauma or seizures; unstable
cardiovascular, endocrine, hematologic, renal or neurologic
disease (determined by physical examination and laboratory
testing); hepatitis B or C or human immunodeficiency virus
infection (by medical history); current or past history of
schizophrenia or bipolar disorder or a current diagnosis of major
depression [as determined by Structured Clinical Interview for
Diagnostic and Statistical Manual of Mental Disorders–Fourth
Edition (SCID)][24]. Subjects with anxiety disorders were not
excluded. Subjects between the ages of 18 and 60 years of age who
met criteria for the fMRI study were then invited to the Emory
General Clinical Research Center for a fMRI scanning session as
described below. The sample was recruited on a 1:2 ratio basis
(CFS:control).
Exclusion Criteria for fMRI
Exclusion criteria for all subjects included: left-handedness (to
minimize the variance associated with the effect of handedness on
brain structure and function); presence of metal in the body;
claustrophobia; and a reading level below grade 7 (as determined
by the WRAT 3, to assure comprehension of written instructions
during the gambling task). Subjects with a score .60 on the 20-
item, self report Zung Self Rating Depression Scale (Zung
SDS)(indicating more than mild depressive symptoms) were also
excluded [25]. All subjects were required to be free of psychotropic
medications including antidepressant, antipsychotic, mood stabi-
lizer or anti-anxiety medications for at least 4 weeks prior to brain
imaging procedures. No subjects were taken off psychotropic
medications for the purposes of the study. Other medications (see
Table 1) were not exclusionary. Subjects with a history of alcohol/
psychoactive substance abuse or dependence within the past year,
as determined by SCID, were excluded. Urine drug screens were
conducted prior to all brain scans to rule out active substance
abuse.
fMRI Imaging Task
A previously published gambling task, proven effective in
eliciting specific activation of basal ganglia structures, was adapted
for the study [19,21]. In the task, participants had to guess which
of two cards presented face-down on a screen was ‘‘red’’ (hearts or
diamonds) by pressing one of two buttons on a MRI response box
held in their right hand. Two seconds into the trial, the selected
card was turned over, and, depending on its color, the participant
either won (red card) or lost (black card) one dollar. Unbeknownst
to the subject, the sequence of wins and losses was temporally
arranged as a noisy sinusoid with a slow linear trend that favored
wins over time. This procedure allowed for experimental control
of the task while masking the deterministic nature of the game
from the participant, thereby eliciting a realistic feeling of
gambling while playing. At the beginning of the game, each
participant started with a credit of $16 and ended with a total win
sum of $23, which the volunteer believed was contingent on his/
her specific gambling choice but was in fact fixed for all subjects.
fMRI Processing and Analyses
Three T2*-weighted functional runs [gradient echo-planar
imaging (EPI), TR: 2.35 s, TE: 28 ms, 135 volumes/run, voxel
size: 3 mm isotropic, 64664 voxel matrix, 35 slices] and a high-
resolution T1-weighted anatomical scan (MPRAGE, TR: 2.3 s,
TE: 3.02 ms, 1 mm isotropic voxels, whole-brain coverage) were
collected on a Siemens Trio 3T MRI scanner. All fMRI processing
was performed using the Analysis of Functional NeuroImage
(AFNI) software package [26]. For each subject, the three EPI runs
were corrected for slice-acquisition timing and aligned via a rigid-
body transformation to a common reference EPI volume to
minimize artifacts from head motion. The anatomical volume was
co-registered to the EPI reference volume and then spatially
normalized to the Talairach-Tournoux standard stereotaxic brain
space. The same transformation was used to warp all functional
volumes to standard space. Each volume was smoothed with a
4 mm-FWHM Gaussian kernel and intensity-normalized to a
percent change relative to the run’s temporal mean on a voxel-
wise basis. Task-related activation maps were computed for each
subject using AFNI’s Restricted Maximum Likelihood procedure
that minimizes the temporal auto-correlation of the scans prior to
ordinary least squares model fit. The model matrix was block-
diagonal, one block per run. Each block contained (a) a baseline
model of four Legendre polynomials (degree zero to three) plus six
motion parameters, to account for signal drifts and head motion
residual confounds, and (b) two task regressors modeling the trials
when a red card (Win) and a black card (Lose) were selected
respectively, obtained by convolving the corresponding stimulus
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timing vectors with a standard hemodynamic gamma function.
General linear tests were used to compute the Win-Lose contrast
combined over all three runs.
To focus the analysis on the specific basal ganglia regions
activated by the task, the following procedure was employed: (1) a
whole-brain group analysis revealing the general activation pattern
for the Win-Lose contrast across all subjects was performed; (2) the
resultant statistical parametric brain map thresholded at p,0.05,
corrected for multiple comparisons, was intersected with basal
ganglia regions of interest (ROIs: caudate nucleus, putamen, and
globus pallidus), obtained from a probabilistic cytoarchitectonic
brain atlas included in the AFNI distribution; (3) for each subject,
the average value of Win-Lose activation contrast in each ROI
was extracted for group comparisons and correlational analyses.
Illness Assessment
To determine the status of participant’s illness at the time of the
scan, questionnaires were administered the evening before the
scan. Fatigue was assessed using the 20-item Multidimensional
Fatigue Inventory (MFI) 20, a self-rating scale yielding specific
Table 1. Sociodemographic and Clinical Characteristics of the Study Sample.
Characteristic Control (n= 41) CFS (n=18) p value
Age (yrs.) – mean (SD) 47.2 (9.2) 44.2 (11.1) 0.28
Sex (female) – no. (%) 33 (80.0%) 16 (88.9%) 0.71
Ethnic Origin - no. (%) 0.48
Caucasian 35 (85.4%) 14 (77.8%)
Black 6 (14.6%) 4 (22.2%)
Education (Highest Degree) – no. (%) 0.66
Graduate Degree 11 (26.8%) 7 (38.9%)
College Graduate 9 (22.0%) 5 (27.8%)
Partial College 16 (39.0%) 4 (22.2%)
High School Graduate 4 (9.8%) 1 (5.6%)
Junior High School 1 (2.4%) 1 (5.6%)
BMI (kg/m2) – mean (SD) 26.7 (5.1) 28.1 (4.6) 0.35
Zung SDS – mean (SD) 32.5 (4.5) 51.7 (9.4) ,0.0001*
SF-36 – mean (SD)
Bodily Pain 89.0 (11.3) 49.5 (17.7) ,0.0001*
General Health 91.1 (7.6) 52.6 (21.5) ,0.0001*
Mental Health 92.6 (5.2) 68.2 (18.1) ,0.0001*
Physical Functioning 96.5 (5.4) 64.4 (25.9) ,0.0001*
Role-Emotional 99.2 (5.2) 64.8 (45.0) ,0.0005*
Role-Physical 99.4 (3.9) 51.4 (45.8) ,0.005*
Social Functioning 98.8 (6.1) 67.4 (22.7) ,0.0001*
Vitality 86.3 (9.6) 40.3 (20.3) ,0.0001*
CDC Symptom Inventory – mean (SD)
CFS Symptoms 0.4 (0.7) 4.6 (1.8) ,0.0001*
Total Symptoms (CFS + non-CFS) 1.1 (1.4) 8.1 (3.9) ,0.0001*
CFS Case Definition Subscale 1.1 (2.3) 37.4 (23.0) ,0.0001*
Medication Usage – no (%)
Anti-inflammatory 11 (27%) 6 (33%) 0.76
Hormonal 15 (37%) 6 (33%) 1.00
Analgesica 3 (7%) 3 (17%) 0.36
Gastrointestinal 9 (22%) 6 (33%) 0.52
Anti-Allergy 12 (29%) 6 (33%) 0.77
Cardiovascularb 14 (34%) 6 (33%) 1.00
Supplementsc 23 (56%) 7 (39%) 0.27
Sleep Aids 1 (2%) 1 (6%) 0.52
yrs-years; SD-standard deviation; no.-number; BMI-body mass index; Zung SDS-Zung Self Rating Depression Scale; SF-36: Short-Form (36) Health Survey; CFS-Chronic
Fatigue Syndrome;
*- Welch Test;
a- one subject in each group used narcotic analgesics;
b- anti-hypertensive medications and cholesterol lowering medications;
c- vitamins and herbal preparations.
doi:10.1371/journal.pone.0098156.t001
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subscales for general fatigue, physical fatigue, reduced activity,
reduced motivation and mental fatigue, with the summed score for
each subscale ranging from 4 (best) to 20 (worst)[27]. Perceived
health and function was measured by the Short Form (36) Health
Survey (SF-36), a self-rating tool that provides eight subscale scores
including bodily pain, general health perceptions, mental health,
physical functioning, emotional role functioning, physical role
functioning, social role functioning and vitality. Higher scores
indicate better perceived health and function. Symptoms of CFS
were assessed by the CFS Symptom Inventory, which is a self-
report instrument that collects information about the presence,
frequency and intensity of fatigue and 18 illness-related symptoms
over the past month period [28,29]. Finally, symptoms of
depression were measured by the Zung Self-rating Depression
Scale (SDS), a 20-item self-report scale which measures the
presence of a variety of depressive symptoms including depressed
mood, anhedonia, concentration problems, sleep difficulties,
fatigue, self-esteem, bodily complaints and suicidal ideation over
the past several days. Higher scores indicate greater severity of
depressive symptoms [25].
Statistical Analysis
Differences between groups in sociodemographic and clinical
variables were assessed using t-tests for continuous measures and
chi-square tests (or Fisher’s Exact Test where appropriate) for
categorical variables. In cases of unequal variances, Welch’s t-test
was employed. Evoked activity in right, left and bilateral caudate,
putamen and globus pallidus was determined by averaging the
estimated percent blood oxygen level-dependent (BOLD) signal
change corresponding to the Win-Lose contrast across all ROI
voxels as described above. Differences in overall neural activity
between groups across ROIs in the three right and left basal
ganglia nuclei (caudate, putamen and globus pallidus) were
analyzed using a multivariate analysis of covariance (MANCOVA)
controlling for age sex, race and body mass index (BMI) as well as
the presence or absence of an anxiety disorder or the use of
medications categorized by class (see Table 1). The impact of these
covariates on neural activity in these basal ganglia nuclei of CFS
subjects only was also assessed using multivariate regression
analyses. Given that the omnibus F-test was significant, univariate
analyses (t-tests) were then performed to investigate group
differences in specific ROIs. Relationships between dimensions
of fatigue as measured by the MFI and evoked activity in those
ROIs that significantly differed between groups were assessed in
each group separately using Bravais-Pearson correlations.
Results
Sociodemographic characteristics and clinical variables
Eighteen CFS patients and 41 healthy controls qualified for the
study and completed the fMRI procedure. Subjects were well-
matched on age, sex, race, education, BMI and medication status
(Table 1). However, as expected, CFS patients exhibited
significantly higher levels of depressive symptoms, lower perceived
health and function and a greater number of CFS- and non-CFS
defining symptoms (Table 1). Significantly greater scores for all
dimensions of fatigue were also observed in the CFS group
compared to controls (Table 2). Six CFS patients had a current
diagnosis of one or more anxiety disorders (1 with obsessive
compulsive disorder, 1 with post traumatic stress disorder, 2 with
generalized anxiety disorder, and 4 with a phobic disorder. No
control subject had a diagnosis of an anxiety disorder.
Neural Activity in Response to the Gambling Task
As shown in Figure 1, in the sample as a whole, there was a
marked increase in neural activity in the Win-Lose condition as
indicated by an increased BOLD signal throughout basal ganglia
structures including the caudate, putamen and globus pallidus.
Comparison of the neural activity between CFS and controls
across the basal ganglia nuclei revealed a significant overall effect
of group controlling for age, sex, race and BMI (F[1,53] = 2.9,
p = 0.02). The overall group effect was also observed when
controlling for the presence or absence of an anxiety disorder or
when controlling for each category of medication individually
(along with age, race, sex, and BMI) (all p,0.05). In addition,
neural activity in the various basal ganglia nuclei of CFS subjects
only was not significantly related to the presence or absence of an
anxiety disorder (p = 0.48) or whether or not subjects were taking a
medication from each of the individual categories indicated in
Table 1 analyzed in conjunction with age, race, sex and BMI (all
p.0.05). Univariate analyses revealed that CFS subjects exhibited
significantly reduced activation for winning versus losing trials
compared to controls in the right caudate (CFS: 0.0576 SD 0.086
versus control: 0.116 6 SD 0.051, p = 0.014) and right globus
pallidus (CFS: 0.035 6 SD 0.071 versus control: 0.079 6 SD
0.053, p = 0.019) (Figure 2). Significant decreases were also found
in CFS subjects versus controls in the bilateral caudate nucleus
(CFS: 0.066 6 SD 0.083 versus control: 0.110 SD 6 0.047,
p = 0.047) and bilateral globus pallidus (CFS: 0.043 6 SD 0.071
versus control: 0.075 6 SD 0.045, p = 0.036), but these differences
did not reach significance when the left side was considered alone
(data not shown).
Correlational Analyses between Symptoms and Basal
Ganglia Activation
In CFS subjects, strong correlations were found between
reduced evoked activity in the right globus pallidus and symptoms
of fatigue, with the highest correlations occurring in association
with mental fatigue (r2 = 0.491, p= 0.001), general fatigue
(r2 = 0.338, p= 0.011) and reduced activity (r2 = 0.293, p= 0.02)
subscales of the MFI (Figure 3). Similar significant relationships
were observed for the physical fatigue subscale (r2 = 0.24, p= 0.04)
but not for the reduced motivation subscale of the MFI (r2 = 0.03,
p = 0.47). No significant correlations were found between symp-
toms of fatigue and the right caudate nucleus in CFS subjects. In
addition, there were no significant correlations in control subjects
between basal ganglia activation in any of the identified ROIs and
fatigue symptoms (Table 2). The measured correlation coefficients
between neural activity and fatigue in CFS subjects in the right
globus pallidus were not significantly changed after controlling for
age, sex, race and BMI (data not shown).
Discussion
CFS subjects exhibited reduced neural activation to a reward
task in caudate and globus pallidus, which in turn was correlated
with symptoms of fatigue. These data suggest that basal ganglia
circuits, especially those involving the globus pallidus, are
associated with the expression of fatigue in CFS subjects. In
addition, the data suggest that the neurocircuitry of fatigue in CFS
patients may share a similar basis in the basal ganglia as is
observed in other neurologic disorders and cases of basal ganglia
lesions, as well as in the context of immune activation.
The observed reduction in the response of the globus pallidus to
the gambling task which correlated with symptoms of fatigue in
CFS patients is consistent with previous studies on this basal
ganglia region. The pars interna of the globus pallidus (GPi), along
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with the substantia nigra pars reticulata, are main basal ganglia
outputs to the thalamus and receive significant dopaminergic
projections from the substantia nigra as well as inhibitory GABA
input from the striatum [30,31]. A loss of the dopaminergic input
to the striatum, which characterizes Parkinson’s disease, leads to
the hyper-activity of the GPi and the subthalamic nucleus
(STN)[32,33], an observation that has led both nuclei to become
targets for deep brain stimulation in the treatment of Parkinson’s
disease [34,35]. DBS in Parkinson’s disease primarily works by
decreasing the abnormally-high neural transmission in the GPi or
STN [36]. However, a potential side effect of DBS in Parkinson’s
disease is the onset of apathy which is believed to be secondary to
decreased pallidal responsivity, a finding in agreement with our
observation of increased symptoms of fatigue in the context of
reduced pallidal responses to reward stimuli. Similarly, a consistent
body of clinical data on cerebrovascular insults has associated
apathy with a disruption of the normal activity of the GPi and its
related thalamo-frontal and prefrontal circuits [37,38], character-
ized by the inability to initiate thoughts or behaviors [39]. Finally,
studies from the animal literature strongly implicate the globus
pallidus in reward, motivation, and effort-related choice behavior
[40–42], all processes that have been found to be critically affected
in CFS patients. Thus, alterations in globus pallidus activation,
possibly secondary to disruptions in neurotransmitter inputs
involving GABA and dopamine, may contribute to symptoms of
fatigue in patients with CFS. Of note, we observed a significant
decrease of task-related activation in CFS patients compared to
control subjects in the right caudate nucleus and in the right
globus pallidus, where the amplitude of the effect in the latter
structure was correlated with symptoms of fatigue. The potential
cause for the right-hemisphere predominance of the findings is a
matter of speculation. Small hemispheric asymmetries in morpho-
metric measures of the basal ganglia have been previously
reported in healthy subjects [43], as well as in patients with
attention deficit disorder (ADHD), where a dysfunction of a right-
sided striatal-prefrontal circuit has been proposed to underlie the
attentional deficits [44]. Perhaps more relevant to our current
findings, a similarly right-hemisphere biased effect as the one
reported herein was observed in a PET study using a radioisotope
of the dopamine precursor L-DOPA in patients with Parkinson’s
disease, with the degree of impaired dopamine uptake in the right
caudate nucleus correlating significantly with the level of cognitive
impairment [45]. Finally, an earlier study of neurotransmitters
distributions in post-mortem human brains found that individuals
with lower amounts of total dopamine tended to concentrate
dopamine in the left putamen and globus pallidus, compared to
their right-sided counterparts [46]. Although the precise role and
meaning of hemispheric differences in basal ganglia function will
need to be clarified by future larger and more focused studies, the
latter finding supports the hypothesis of a general hypofunctional
dopaminergic system in CFS that exposes the right basal ganglia
structures to a greater vulnerability.
One mechanism that may contribute to alterations in function
and neurotransmission in the basal ganglia in CFS is inflammation
[47]. CFS patients have been shown to exhibit a number of
immune alterations including the presence of increased inflam-
matory markers in the peripheral blood and increased production
of inflammatory cytokines in ex vivo preparations of peripheral
blood mononuclear cells [12–15]. As noted above, a number of
inflammatory stimuli including the inflammatory cytokine, inter-
feron alpha and cytokine inducers such as endotoxin and typhoid
vaccination have been shown to alter basal ganglia function while
also leading to symptoms of fatigue including psychomotor slowing
and reduced motivation, both fundamental behavioral processes
regulated by basal ganglia structures [19,20,47,48]. Recent work
in humans and non-human primates suggests that some of the
effects of inflammatory stimuli, in particular interferon alpha, are
mediated by effects on basal ganglia dopamine [19,49]. Indeed,
studies in humans using positron emission tomography have
shown increased uptake and decreased turnover/release of the
dopamine precursor, L-DOPA [19]. Similar results have been
Table 2. Symptoms of Fatigue in CFS and Control Subjects.
MFI Subscale Control (n = 41) CFS (n=18) t statistic p value*
Mean (SD) Mean (SD)
General Fatigue 6.0 (1.6) 14.7 (3.2) 10.9 ,0.0001
Physical Fatigue 5.6 (2.3) 12.2 (4.5) 5.8 ,0.0001
Reduced Activity 5.0 (1.3) 10.4 (5.1) 4.4 ,0.001
Reduced Motivation 5.3 (1.5) 10.2 (2.7) 7.2 ,0.0001
Mental Fatigue 5.8 (1.8) 12.7 (3.8) 7.3 ,0.0001
CFS-Chronic Fatigue Syndrome; MFI-Multidimensional Fatigue Inventory; SD-Standard deviation;
*-Welch test.
doi:10.1371/journal.pone.0098156.t002
Figure 1. Basal Ganglia Activation in the Gambling Task. Left to
right - Axial, coronal and transverse sections of the brain. The top row
displays the activation for the Win-Lose contrast, for the pooled sample
of chronic fatigue syndrome (CFS)+Control subjects, as a statistical
parametric map thresholded at a p,0.05 corrected threshold and
masked with the atlas-based anatomical regions of interest portrayed in
the bottom row (putamen: purple; caudate: orange; globus pallidus:
turquoise).
doi:10.1371/journal.pone.0098156.g001
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found in rhesus monkeys administered interferon alpha [49].
Using in vivo microdialysis from probes implanted in the caudate,
dopamine release was found to be decreased after 4 weeks of
interferon alpha, consistent with the reduced neural activation in
basal ganglia nuclei seen in humans using fMRI in both interferon
alpha-treated subjects as well as patients with CFS [19,49]. Of
note, interferon alpha is a cytokine well known to be released
during viral infections, and increased levels of central nervous
system interferon alpha have been associated with behavioral
deficits in animal models of human immunodeficiency virus (HIV)
and HIV patients [50,51]. Thus, the activation of inflammatory
pathways by viruses or other pathogens – as well as in a variety of
conditions known to be associated with increased inflammation,
including obesity and psychosocial stress – may represent one
mechanism of altered basal ganglia function leading to symptoms
of fatigue in patients with CFS. Given mechanistic data suggesting
that altered dopamine availability may be a consequence of
inflammatory effects on the brain, our findings suggest that a good
avenue for future studies might be exploring whether drugs that
increase dopamine availability in the brain would reduce symptom
expression in some CFS patients who exhibit basal ganglia
changes and/or increased inflammation.
There are several strengths and weaknesses of this study which
should be considered in the interpretation of the data. First, the
sample size of CFS subjects was relatively small. Although there
were many more CFS subjects identified by our initial sampling
strategy, we adhered to strict inclusion and exclusion criteria to
limit the potential influence of factors such as psychotropic
medications and psychiatric conditions like depression, both of
which can have a profound effect on neuroimaging data.
Moreover, we used validated assessment tools to quantify the
degree of pathology in each of the domains relevant to the
diagnosis of CFS. This attempt to provide a relatively homogenous
sample of CFS patients also runs the risk of producing results that
are not generalizable to the ‘‘typical’’ CFS patient. In addition,
these data represent averaged results from each of the samples,
and observation of the data indicates there was significant overlap
between the groups. Thus, not all persons in our study exhibited
reduced neural activation in the basal ganglia, although all CFS
subjects exhibited significant fatigue. Therefore, although alter-
ations in basal ganglia function may characterize a subgroup of
CFS patients, such alterations do not typify all CFS subjects and
do not account for all instances of fatigue. In this study non-
fatigued controls were used as the comparison group as a starting
place in investigating biologic associations with CFS. These non-
fatigued controls exhibited some low level of minor medical
problems including allergies, muscle aches and pains, gastrointes-
tinal distress, high blood pressure and hypercholesterolemia for
which they were taking medications, but not at rates that differed
from our CFS sample. Nevertheless, in order to evaluate whether
the findings are specific to CFS, additional studies comparing
persons with CFS to persons with more significant illnesses or
chronic fatigue would be useful to determine if our findings are
typical of CFS patients, or patients with fatigue or illness in
general. Finally, it should be noted that the CFS patients in this
study were not drawn from a sample of subjects seeking care at an
academic or private practice specialty clinic providing tertiary
care. Rather the subjects studied herein were a community-based
sample, and despite the rigorous inclusion and exclusion criteria,
might more likely reflect findings in the average patient.
Conclusions
CFS subjects free of psychotropic medications and without
significant psychiatric disease were found to exhibit reduced
activation of basal ganglia structures that correlated with
symptoms of fatigue. The findings are consistent with diseases
Figure 2. Reduced Activation in Basal Ganglia Structures in CFS compared to Controls for the Win-Lose Contrast. Box plot of
activation [percent blood oxygen level-dependent (BOLD) signal change corresponding to the Win-Lose contrast averaged across all region of
interest (ROI) voxels] in basal ganglia structures: blue = nonfatigued (NF) controls, red = chronic fatigue syndrome (CFS) subjects. Univariate
analyses of group differences in specific ROIs revealed that CFS subjects exhibited significantly reduced neural activity compared to NF controls in the
right caudate and right globus pallidus and each of these structures bilaterally (all p,0.05).
doi:10.1371/journal.pone.0098156.g002
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known to affect the basal ganglia and are consistent with basal
ganglia changes seen after administration of a variety of stimuli
that induce an inflammatory response.
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